John Goldberg
Chief Tech/Sci/R&D Officer chez RAFAEL HOLDINGS, INC.
Fortune : 344 $ au 31/12/2023
Profil
John M.
Goldberg is currently the Chief Medical Officer at Rafael Holdings, Inc. Prior to this, he was the Chief Medical Officer at Oncorus, Inc. from 2018 to 2023.
He also held the position of Senior Director-Medical at H3 Biomedicine, Inc. and Head-Clinical Development at Agenus, Inc. Dr. Goldberg received his undergraduate degree from The University of Chicago and his doctorate from the University of Massachusetts Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ONCORUS, INC.
0,01% | 31/03/2023 | 2 730 ( 0,01% ) | 344 $ | 31/12/2023 |
Postes actifs de John Goldberg
| Sociétés | Poste | Début |
|---|---|---|
| RAFAEL HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 20/11/2023 |
Anciens postes connus de John Goldberg
| Sociétés | Poste | Fin |
|---|---|---|
| ONCORUS, INC. | Chief Tech/Sci/R&D Officer | 30/06/2023 |
| AGENUS INC. | Chief Tech/Sci/R&D Officer | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - |
Formation de John Goldberg
| The University of Chicago | Undergraduate Degree |
| UMass Chan Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AGENUS INC. | Health Technology |
| ONCORUS, INC. | Health Technology |
| RAFAEL HOLDINGS, INC. | Finance |
| Entreprise privées | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
